AN2 Therapeutics (ANTX) Research & Development (2021 - 2026)

AN2 Therapeutics (ANTX) has 6 years of Research & Development data on file, last reported at $6.7 million in Q1 2026.

• On a quarterly basis, Research & Development fell 12.31% year-over-year to $6.7 million in Q1 2026; TTM through Mar 2026 was $23.8 million, a 28.94% decrease from a year earlier, with the FY2025 full-year figure at $24.8 million, down 38.82% from the prior year.
• Research & Development for Q1 2026 stood at $6.7 million, down from $6.9 million in the prior quarter.
• Over the last five years, Research & Development for ANTX reached as high as $14.9 million in Q4 2023 and fell as low as $3.2 million in Q2 2025.
• Historically, Research & Development has averaged $9.1 million across 5 years, with a median of $7.7 million in 2025.
• Across the five-year window, Research & Development soared 241.6% in 2022 and slumped 73.66% in 2025, its largest moves.
• Year by year, Research & Development stood at $8.8 million in 2022, then jumped by 70.46% to $14.9 million in 2023, then tumbled by 63.82% to $5.4 million in 2024, then advanced by 27.46% to $6.9 million in 2025, then declined by 1.98% to $6.7 million in 2026.
• Per Business Quant data, the three most recent Research & Development figures were $6.7 million in Q1 2026, $6.9 million in Q4 2025, and $7.0 million in Q3 2025.